文献速递银屑病与炎症性皮肤病

卤倍他索与他扎罗汀固定复方制剂治疗中重度斑块状银屑病的疗效与安全性:两项3期随机对照试验结果

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
PubMed 文献 · J Am Acad Dermatol · 2018-04-01

两项多中心、随机、双盲、溶媒对照的3期研究(N=418)评估了丙酸卤倍他索0.01%联合他扎罗汀0.045%洗剂(HP/TAZ)治疗中重度斑块状银屑病。受试者按2:1随机分配接受HP/TAZ洗剂或溶媒每日一次治疗8周,并随访4周。结果显示HP/TAZ在治疗成功率和改善银屑病体征、症状及受累体表面积方面均优于溶媒,未观察到安全性问题。

要点

  • HP/TAZ在治疗2周内即显示出优于溶媒的统计学显著性。
  • 第8周时,研究1和研究2中HP/TAZ组治疗成功率分别为35.8%和45.3%,溶媒组分别为7.0%和12.5%(P<.001)。
  • 最常见治疗相关不良事件为接触性皮炎(6.3%)、用药部位疼痛(2.6%)和瘙痒(2.2%)。

核心结论

  • HP/TAZ洗剂与银屑病临床体征严重程度显著降低相关,且未观察到安全性问题。

研究设计与样本

  • 两项多中心、随机、双盲、溶媒对照的3期研究(N=418),受试者按2:1随机分配接受HP/TAZ洗剂或溶媒每日一次治疗8周,并随访4周。

主要发现

  • HP/TAZ洗剂在治疗2周内即显示出统计学显著优于溶媒的疗效。
  • 第8周时,研究1中HP/TAZ组治疗成功率为35.8%,溶媒组为7.0%(P<.001)。
  • 第8周时,研究2中HP/TAZ组治疗成功率为45.3%,溶媒组为12.5%(P<.001)。
  • HP/TAZ洗剂在改善银屑病体征、症状及受累体表面积方面亦优于溶媒。
  • 最常见治疗相关不良事件为接触性皮炎(6.3%)、用药部位疼痛(2.6%)和瘙痒(2.2%)。

关键数值与推荐

  • 主要疗效终点为治疗成功,即研究者总体评估(IGA)评分较基线至少改善2级且评分为清除或几乎清除。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究未纳入银屑病受累体表面积超过12%的受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical corticosteroids are the mainstay of psoriasis treatment, with long-term safety considerations limiting their use. Combining them with tazarotene may optimize their efficacy and minimize safety and tolerability concerns. OBJECTIVE: To investigate the safety and efficacy of halobetasol propionate 0.01% plus tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis. METHODS: Two multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (N = 418) were conducted. Subjects were randomized (2:1) to HP/TAZ lotion or vehicle once daily for 8 weeks with a 4-week follow-up. The primary efficacy assessment end point was treatment success (at least a 2-grade improvement from baseline in Investigator's Global Assessment score and a score of clear or almost clear). Safety and treatment-emergent adverse events were evaluated throughout. RESULTS: HP/TAZ lotion demonstrated statistically significant superiority over vehicle within as few as 2 weeks. By week 8, 35.8% (study 1) and 45.3% (study 2) of subjects were treatment successes compared with 7.0% and 12.5% of those treated with vehicle (P < .001). HP/TAZ lotion was also superior in reducing signs and symptoms of psoriasis and body surface area affected by psoriasis. The most frequently reported treatment-related adverse events were contact dermatitis (6.3%), application site pain (2.6%), and pruritus (2.2%). LIMITATIONS: Studies did not include subjects with more than 12% of their body surface area affected by psoriasis. CONCLUSIONS: HP/TAZ lotion was associated with significant reductions in the severity of the clinical signs of psoriasis, with no safety concerns.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018. PMID: 29614243. doi:10.1016/j.jaad.2018.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。